Remove articles pharmaceutics
article thumbnail

Why is pharma going gaga for radiopharmaceuticals?

pharmaphorum

Pharmaceutical companies are increasingly focusing on radiopharmaceuticals due to their potential in oncology and therapeutic applications. Learn more about why the industry is excited about radioisotopes in this article.

article thumbnail

Redefining pharmaceutical case processing in the age of AI and automation

pharmaphorum

Discover how AI, automation, and blockchain technologies are revolutionising pharmaceutical case processing in compliance with FDA regulations. Explore the benefits of these advancements in this insightful article.

FDA 115
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Driving QbD as a quality standard in drug development

European Pharmaceutical Review

A paper published in the European Journal of Pharmaceutics and Biopharmaceutics has reviewed the current application status of Quality by Design (QbD) within the framework of the ICH guidelines (ICH Q8(R2) – Q14 and ICH Q2(R2)). For example, Simões et al.

article thumbnail

To fight rare diseases, win the data battle first

pharmaphorum

This article explores how pharmaceutical companies are leveraging AI and focusing on orphan drugs to tackle rare diseases. To effectively combat rare diseases, it is essential to prioritise the collection and analysis of data.

article thumbnail

The race for obesity drug assets heats up

pharmaphorum

The race for obesity drug assets is becoming more intense as pharmaceutical companies strive to develop effective treatments for weight loss. This article explores the efficacy, potential sales, and market trends in the field of obesity drugs.

article thumbnail

Big pharma places big bets on antibody-drug conjugates

pharmaphorum

This article explores the growing interest and recent developments, including FDA approvals and the potential impact on the pharmaceutical industry. Big pharma companies like Pfizer are making significant investments in antibody-drug conjugates, a promising class of therapies.

FDA 110
article thumbnail

European Pharmaceutical Review Issue 2 2024

European Pharmaceutical Review

Articles included in Issue 2 of European Pharmaceutical Review – our cell and gene therapy focus – include: CELL & GENE THERAPY Proper planning prevents CMC disasters for cell and gene therapies Drew Hope, Ryan Guest and Clare Blue eXmoor Pharma SUPPLY CHAIN Fresh or frozen?

81